DOI: 10.26717/BJSTR.2017.01.000139
*Corresponding author:
Nahla A M Hamed, Faculty of Medicine, Alexandria University, EgyptReceived: June 14, 2017 Published: June 16, 2017
To view the Full Article Peer-reviewed Article PDF
AML is a heterogeneous disease and is the most common acute leukemia in adults. It has an annual US incidence over 20,000 and death rate of over 10,000 per year. The 5-year remission rates after conventional induction therapy is 40% below 60 years and 10%-20% in older patients. FLT3-ITD mutation has been added to the WHO risk stratification as a predictor of poor prognosis. On April 28, 2017 FDA approved midostaurinin combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for treating adult newly diagnosed AML patients who are FLT3 mutation positive as detected by an FDA approved test.
Abbreviations: AML: Acute Myeloid Leukemia; CR: Complete Remission; DFS: Disease -Free Survival; OS: Overall Survival; ITD: Internal Tandem Duplication; FLT3: Fms-Like Tyrosine kinase 3; RTK: Receptor Tyrosine Kinase; TKI: Tyrosine Kinase Inhibitors; FL: FLT3 Ligand; PIM: Proviral Integration site; MDS: Myelodysplastic Syndrome; DLI: Donor Lymphocyte Infusion; ATP: Adenosine Triphosphate; PDGFR: Platelet Derived Growth Factor Receptor; VEGFR: Vascular Endothelial Growth Factor receptor; AEs: Adverse Events
Introduction | Conclusion | References |